Descriptor English: | BNT162b5 | ||||||
Descriptor Spanish: |
BNT162b5
| ||||||
Descriptor Portuguese: | BNT162b5 | ||||||
Descriptor French: | Without translation | ||||||
Entry term(s): |
COVID 19 Vaccine Pfizer BioNTech, Bivalent COVID-19 Vaccine Pfizer-BioNTech, Bivalent Pfizer BioNTech COVID 19 Vaccine, Bivalent Pfizer-BioNTech COVID-19 Vaccine, Bivalent |
||||||
Tree number(s): |
D12.776.828.868.228.500.875 D20.215.894.815.750 D20.215.894.865.450.500.875 D20.215.894.899.085.750 D23.050.865.450.500.875 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D000096106 | ||||||
Scope note: | A combined mRNA vaccine, developed by Pfizer and BioNTech against SARS-CoV-2 with a mixture of the original strain of SARS-CoV-2 and BA.4 and BA.5 lineages of the omicron variant of SARS-CoV-2. |
||||||
Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BI biosynthesis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics GE genetics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||||
Public MeSH Note: | 2024 |
||||||
History Note: | 2024 |
||||||
DeCS ID: | 60466 | ||||||
Unique ID: | D000096106 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 2024/01/01 | ||||||
Date of Entry: | 2023/07/26 | ||||||
Revision Date: | 2023/05/22 |
-
-
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins -
CHEMICALS AND DRUGS
Complex Mixtures [D20]Complex Mixtures -
CHEMICALS AND DRUGS
Complex Mixtures [D20]Complex Mixtures -
CHEMICALS AND DRUGS
Complex Mixtures [D20]Complex Mixtures -
CHEMICALS AND DRUGS
Biological Factors [D23]Biological Factors
|
BNT162b5
- Preferred
COVID-19 Vaccine Pfizer-BioNTech, Bivalent
- Broader
Concept UI |
M000759679 |
Scope note | A combined mRNA vaccine, developed by Pfizer and BioNTech against SARS-CoV-2 with a mixture of the original strain of SARS-CoV-2 and BA.4 and BA.5 lineages of the omicron variant of SARS-CoV-2. |
Preferred term | BNT162b5 |
Concept UI |
M000759678 |
Preferred term | COVID-19 Vaccine Pfizer-BioNTech, Bivalent |
Entry term(s) |
COVID 19 Vaccine Pfizer BioNTech, Bivalent Pfizer BioNTech COVID 19 Vaccine, Bivalent Pfizer-BioNTech COVID-19 Vaccine, Bivalent |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey